SEC Filing Summary: Form 13F-HR
Business Context and Reporting Period
This filing is a Form 13F-HR (Holdings Report) submitted by Takeda Pharmaceutical Co Ltd, an institutional investment manager based in Tokyo, Japan. The report covers the calendar quarter ended June 30, 2025, and was signed on August 7, 2025, by Amit Singh, Senior Vice President and Head of Treasury.
The report includes holdings for Takeda Pharmaceutical Co Ltd and one other included manager: Takeda Vaccines, Inc.
Key Financial Metrics
As a Form 13F filing, this document discloses equity holdings rather than the company's operational financial performance. Consequently, the filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for Takeda Pharmaceutical Co Ltd.
- Total Value of Reported Holdings: $19,553,783 (rounded to the nearest dollar).
- Total Number of Holdings Entries: 12.
- Number of Other Included Managers: 1 (Takeda Vaccines, Inc.).
Material Changes
The filing text provided does not contain comparative data for the prior period (March 31, 2025) or a breakdown of specific securities purchased or sold. Therefore, material changes in holdings versus the prior comparable period cannot be determined from this summary text.
Guidance, Outlook, and Risks
Form 13F filings are statutory disclosures of equity positions and do not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the reporting manager's business operations. The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness.
Investor Verification Checklist
- Verify the specific 12 equity positions held by Takeda Pharmaceutical Co Ltd and Takeda Vaccines, Inc. in the full Schedule 13F-HR to understand the portfolio composition.
- Confirm the total market value of $19,553,783 against the sum of individual holdings to ensure data integrity.
- Note that this filing reflects investment activities, not the operational financial health of Takeda Pharmaceutical Co Ltd; refer to 10-K or 10-Q filings for operational metrics.
- Check for any subsequent amendments to this report filed after August 7, 2025.